These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37468112)

  • 1. A comprehensive review of protein misfolding disorders, underlying mechanism, clinical diagnosis, and therapeutic strategies.
    Basha S; Mukunda DC; Rodrigues J; Gail D'Souza M; Gangadharan G; Pai AR; Mahato KK
    Ageing Res Rev; 2023 Sep; 90():102017. PubMed ID: 37468112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on protein misfolding, aggregation and strategies to prevent related ailments.
    Shamsi TN; Athar T; Parveen R; Fatima S
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):993-1000. PubMed ID: 28743576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectral Fluorescence Pathology of Protein Misfolding Disorders.
    Stepanchuk AA; Stys PK
    ACS Chem Neurosci; 2024 Mar; 15(5):898-908. PubMed ID: 38407017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein aggregation and neurodegenerative diseases: From theory to therapy.
    Kumar V; Sami N; Kashav T; Islam A; Ahmad F; Hassan MI
    Eur J Med Chem; 2016 Nov; 124():1105-1120. PubMed ID: 27486076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
    Scannevin RH
    Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
    Vendruscolo M
    Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanistic insight into protein-ligand interaction, folding, misfolding, aggregation and inhibition of protein aggregates: An overview.
    Chandel TI; Zaman M; Khan MV; Ali M; Rabbani G; Ishtikhar M; Khan RH
    Int J Biol Macromol; 2018 Jan; 106():1115-1129. PubMed ID: 28890370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics.
    Gandhi J; Antonelli AC; Afridi A; Vatsia S; Joshi G; Romanov V; Murray IVJ; Khan SA
    Rev Neurosci; 2019 May; 30(4):339-358. PubMed ID: 30742586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
    Naeem A; Fazili NA
    Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M; Andrisano V
    Chembiochem; 2010 May; 11(8):1018-35. PubMed ID: 20401887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies.
    Khan AN; Khan RH
    Int J Biol Macromol; 2022 Dec; 223(Pt A):143-160. PubMed ID: 36356861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the understanding of protein misfolding and aggregation through molecular dynamics simulation.
    Rahman A; Saikia B; Gogoi CR; Baruah A
    Prog Biophys Mol Biol; 2022 Nov; 175():31-48. PubMed ID: 36044970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives.
    Lee SJ; Lim HS; Masliah E; Lee HJ
    Neurosci Res; 2011 Aug; 70(4):339-48. PubMed ID: 21624403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical kinetics for drug discovery to combat protein aggregation diseases.
    Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Trends Pharmacol Sci; 2014 Mar; 35(3):127-35. PubMed ID: 24560688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Amyloid aggregates: role in Protein Misfolding Disorders].
    Duran-Aniotz C; Moreno-Gonzalez I; Morales R
    Rev Med Chil; 2013 Apr; 141(4):495-505. PubMed ID: 23900371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease.
    Singh N; Haldar S; Tripathi AK; McElwee MK; Horback K; Beserra A
    Antioxid Redox Signal; 2014 Jul; 21(3):471-84. PubMed ID: 24512387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.